Cancer drug developer Celldex Therapeutics Inc. said it would price a stock offering at $3.15 per share and expects to net $29.4 million. The company will use proceeds from the offering to fund clinical trials and for working capital.
Scientists at the University of California, San Diego School of Medicine, and the Eastern Hepatobiliary Surgery Hospital in China, say a human gene implicated in the development of leukemia also acts to prevent liver cancer.
New findings show that treatment with a specific alpha blocker helps reduce symptoms and improve quality of life for men with chronic prostatitis/chronic pelvic pain syndrome.
A team led by developmental biologist, professor Christophe Marcelle has identified the mechanism that causes stem cells in the embryo to differentiate into specialized cells that form the skeletal muscles of animals’ bodies.
A new discovery in mice by researchers at Wake Forest Baptist Medical Center may one day allow doctors to spare patients with acute myeloid leukemia (AML) from toxic treatments.
CytRx Corp. has sold the worldwide rights of its molecular chaperone assets to Orphazyme ApS, completing CytRx’s previously announced, non-dilutive monetization strategy for its non-core assets.
The anti-inflammatory drug celecoxib (Celebrex) triggers liver cancer cell death by reacting with a protein in a way that makes those cells commit suicide, a new study reports.
Researchers were honored with awards commemorating their contributions to the pharmaceutical sciences during the American Association of Pharmaceutical Scientists’ (AAPS) 2011 National Biotechnology Conference. AAPS president Philip R. Mayer, PhD, presented the awards.
Researchers have identified a protein, Abcc10, as being involved in resistance to certain drugs used to treat breast, ovarian, lung, and other cancers
Verona Pharmaceuticals has treated its first patient in a Phase II clinical trial for its lead respiratory drug, RPL554.
EnVivo Pharmaceuticals reported positive results of its randomized, placebo-controlled Phase 2b clinical trial of EVP-6124, an orally bioavailable and selective alpha-7 agonist, in patients with schizophrenia.
Amgen announced primary results of a Phase 3 trial ('147) demonstrating that XGEVA significantly increased bone metastasis-free survival for more than four months in men with castrate-resistant metastatic prostate cancer that has not yet spread to bone.
Shire PLC said that it is buying Advanced BioHealing Inc. for $750 million and will pay for the deal from its current cash stores.
The road to type 2 diabetes is paved with insulin resistance, a condition often associated with obesity in which the hormone begins to fail at its job helping to convert sugars to energy.
Most degenerative diseases begin with a gradual loss of specific cell types that progresses, eventually leading to symptoms. Finding ways to stop early cell destruction is vital, but methods to do so have proven challenging.